Search Results - "Powers, Janine"

Lack of evidence for GDF11 as a rejuvenator of aged skeletal muscle satellite cells by Hinken, Aaron C., Powers, Janine M., Luo, Guizhen, Holt, Jason A., Billin, Andrew N., Russell, Alan J.

“…Summary Recent high‐profile studies report GDF11 to be a key circulating ‘anti‐aging’ factor. However, a screen of extracellular proteins attempting to…”
Get full text

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer by Xiang, Hong, Chan, Abigael G, Ahene, Ago, Bellovin, David I, Deng, Rong, Hsu, Amy W, Jeffry, Ursula, Palencia, Servando, Powers, Janine, Zanghi, James, Collins, Helen

“…Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor…”
Get full text

S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho–Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4 by Spiekerkoetter, Edda, Guignabert, Christophe, de Jesus Perez, Vinicio, Alastalo, Tero-Pekka, Powers, Janine M, Wang, Lingli, Lawrie, Allan, Ambartsumian, Noona, Schmidt, Ann-Marie, Berryman, Mark, Ashley, Richard H, Rabinovitch, Marlene

“…RATIONALE:S100A4/Mts1 is implicated in motility of human pulmonary artery smooth muscle cells (hPASMCs), through an interaction with the RAGE (receptor for…”
Get full text

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma by Catenacci, Daniel V T, Rasco, Drew, Lee, Jeeyun, Rha, Sun Young, Lee, Keun-Wook, Bang, Yung Jue, Bendell, Johanna, Enzinger, Peter, Marina, Neyssa, Xiang, Hong, Deng, Wei, Powers, Janine, Wainberg, Zev A

“…To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal…”
Get full text

Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design by Catenacci, Daniel Vt, Tesfaye, Anteneh, Tejani, Mohamed, Cheung, Eric, Eisenberg, Peter, Scott, Aaron J, Eng, Clarence, Hnatyszyn, James, Marina, Neyssa, Powers, Janine, Wainberg, Zev

“…Bemarituzumab is an afucosylated monoclonal antibody against FGFR2b (a FGF receptor) with demonstrated monotherapy clinical activity in patients with late-line…”
Get full text

Abstract A033: Evaluation of FGFR2b in context of relevant biomarkers supports potential combination of anti-FGFR2b with anti-PD-(L)1 therapy in gastric cancer by Sharma, Khushboo, Schmidt, Maike, Hestir, Kevin, Mendoza, Nerissa, Powers, Janine, Hnatyszyn, James

“…Abstract Background: Gastric cancer is the third leading cause of global cancer-related death, with 782,685 deaths in 2018 (Jemal, A. et al. 2018). Currently…”
Get full text

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127 by Montoya, Skye, Bourcier, Jessie, Noviski, Mark, Lu, Hao, Thompson, Meghan C, Chirino, Alexandra, Jahn, Jacob, Sondhi, Anya K, Gajewski, Stefan, Tan, Ying Siow May, Yung, Stephanie, Urban, Aleksandra, Wang, Eric, Han, Cuijuan, Mi, Xiaoli, Kim, Won Jun, Sievers, Quinlan, Auger, Paul, Bousquet, Hugo, Brathaban, Nivetha, Bravo, Brandon, Gessner, Melissa, Guiducci, Cristiana, Iuliano, James N, Kane, Tim, Mukerji, Ratul, Reddy, Panga Jaipal, Powers, Janine, Sanchez Garcia de Los Rios, Mateo, Ye, Jordan, Barrientos Risso, Carla, Tsai, Daniel, Pardo, Gabriel, Notti, Ryan Q, Pardo, Alejandro, Affer, Maurizio, Nawaratne, Vindhya, Totiger, Tulasigeri M, Pena-Velasquez, Camila, Rhodes, Joanna M, Zelenetz, Andrew D, Alencar, Alvaro, Roeker, Lindsey E, Mehta, Sanjoy, Garippa, Ralph, Linley, Adam, Soni, Rajesh Kumar, Skånland, Sigrid S, Brown, Robert J, Mato, Anthony R, Hansen, Gwenn M, Abdel-Wahab, Omar, Taylor, Justin

“…Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in…”
Get full text

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies by Robbins, Daniel W., Noviski, Mark A., Tan, Ying Siow, Konst, Zef A., Kelly, Aileen, Auger, Paul, Brathaban, Nivetha, Cass, Robert, Chan, Ming Liang, Cherala, Ganesh, Clifton, Matthew C., Gajewski, Stefan, Ingallinera, Timothy G., Karr, Dane, Kato, Daisuke, Ma, Jun, McKinnell, Jenny, McIntosh, Joel, Mihalic, Jeff, Murphy, Brent, Panga, Jaipal Reddy, Peng, Ge, Powers, Janine, Perez, Luz, Rountree, Ryan, Tenn-McClellan, Austin, Sands, Arthur T., Weiss, Dahlia R., Wu, Jeffrey, Ye, Jordan, Guiducci, Cristiana, Hansen, Gwenn, Cohen, Frederick

“…Bruton’s tyrosine kinase (BTK), a member of the TEC family of kinases, is an essential effector of B-cell receptor (BCR) signaling. Chronic activation of…”
Get full text

Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders by Montoya, Skye, Bourcier, Jessie, Thompson, Meghan C., Noviski, Mark, Tan, May, Wang, Eric, Mi, Xiaoli, Brathaban, Nivetha, Barrientos Risso, Carla, Tsai, Daniel, Ye, Jordan, Jahn, Jacob, Pardo, Gabriel, Cabuhat, Lee, Notti, Ryan, Pardo, Alejandro, Affer, Maurizio, Yung, Stephanie, Luliano, James, Powers, Janine, Robbins, Daniel W, Nawaratne, Vindhya, Totiger, Tulasigeri M, Pena-Velasquez, Camila, Rhodes, Joanna M., Zelenetz, Andrew D., Roeker, Lindsey E., Lu, Hao, Linley, Adam, Mato, Anthony R., Abdel-Wahab, Omar, Taylor, Justin

Get full text

FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in by Catenacci, Daniel V.T., Enzinger, Peter C., Tesfaye, Anteneh A., Tejani, Mohamedtaki Abdulaziz, Powers, Janine, Zhang, Charlie, Marina, Neyssa, Eng, Clarence, Cheung, Eric, Scott, Aaron James, Eisenberg, Peter D.

“…Abstract only…”
Get full text

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies by Robbins, Daniel W, Kelly, Aileen, Tan, May, McIntosh, Joel, Wu, Jeffrey, Konst, Zef, Kato, Daisuke, Peng, Ge, Mihalic, Jeff, Weiss, Dahlia, Perez, Luz, Tung, Jennifer, Kolobova, Anna, Borodovsky, Sasha, Rountree, Ryan, Tenn-McClellan, Austin, Noviski, Mark, Ye, Jordan, Basham, Steve, Ingallinera, Timothy, McKinnell, Jenny, Karr, Dane E, Powers, Janine, Guiducci, Cristiana, Sands, Arthur

“…Bruton's tyrosine kinase (BTK) plays a key role in cell survival in B cell malignancies, such as chronic lymphocytic leukemia (CLL). Covalent inhibitors of…”
Get full text

Abstract 1407: FPA144, a therapeutic monoclonal antibody targeting the FGFR2b receptor, promotes antibody dependent cell-mediated cytotoxicity and stimulates sensitivity to PD-1 in the 4T1 syngeneic tumor model by Powers, Janine, Palencia, Servando, Foy, Susan, Sennino, Barbara, Hidalgo, Toni Rose, Gemo, Abigael, Brennan, Thomas, Pierce, Kisten

“…Abstract Five Prime Therapeutics, Inc. has developed an FGFR2b-specific humanized monoclonal antibody, FPA144, to treat patients with cancer bearing…”
Get full text

Abstract 2633: Identification of novel T cell co-inhibitory and co-stimulatory receptors from screening a comprehensive library of extracellular proteins by Brace, Arthur, Sallee, Nathan, Chou, Justin, Garrenton, Lindsay, Chen, Diana, Liang, Ryan, Kemper, Greg, Yang, David, Jaquez, Marina, Powers, Janine, Mkrtichyan, Mikayel, Brennan, Thomas, Borges, Luis

“…Abstract Antibody blockade of immune checkpoint regulators such as PD-1 and CTLA-4 has been shown to be an effective cancer treatment strategy; however, a…”
Get full text

Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications by Carleton, Michael, Powers, Janine, Phillips, Penny, Beg, Muhammad Shaalan, Lee, James J., Rahma, Osama E., Piha-Paul, Sarina Anne, Lee, Ernestine, Hestir, Kevin, Xu, Ke, Pandya, Dimple, Inamdar, Sandeep P., Perna, Serena K, Huang, Shih-Min A., Wainberg, Zev A.

“…Abstract only…”
Get full text

Lack of evidence for GDF 11 as a rejuvenator of aged skeletal muscle satellite cells by Hinken, Aaron C., Powers, Janine M., Luo, Guizhen, Holt, Jason A., Billin, Andrew N., Russell, Alan J.

Get full text

Abstract 1126: Concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing by Noviski, Mark A., Ma, Jun, Lee, Ernestine, Brathaban, Nivetha, Tan, May, Perez, Luz, Robbins, Daniel W., Tenn-McClellan, Austin, Powers, Janine, Hansen, Gwenn, Guiducci, Cristiana, Rountree, Ryan

“…Abstract B-cell receptor (BCR) signaling is integral for the development, adhesion, growth, and survival of human B cells. Chronic activation of BTK-mediated…”
Get full text

S100A4 and BMP-2 Co-Dependently Induce Vascular Smooth Muscle Cell Migration via pERK and Chloride Intracellular Channel 4 (CLIC4) by Spiekerkoetter, Edda, Guignabert, Christophe, de Jesus Perez, Vinicio, Alastalo, Tero-Pekka, Powers, Janine M, Wang, Lingli, Lawrie, Allan, Ambartsumian, Noona, Schmidt, Ann-Marie, Berryman, Mark, Ashley, Richard H, Rabinovitch, Marlene

Get full text

From medicine to art: Nils Paul Larsen (1890–1964) by Powers, Janine A

“…Nils Paul Larsen (1922–1964) was a significant transitional figure in Hawai'i as it was changing from the plantation era to a modern Pacific community. Larsen,…”
Get full text

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer by Xiang, Hong, Chan, Abigael G., Ahene, Ago, Bellovin, David I., Deng, Rong, Hsu, Amy W., Jeffry, Ursula, Palencia, Servando, Powers, Janine, Zanghi, James, Collins, Helen

“…Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor…”
Get full text